We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Consent Decree More Than Likely for Hospira Plant, Analyst Says
Consent Decree More Than Likely for Hospira Plant, Analyst Says
December 6, 2011
Recent feedback from FDA quality control consultants suggests the manufacturing problems bedeviling Hospira, particularly at its Rocky Mount, N.C., plant, will take two to three years to resolve and force the FDA to issue a stock-shocking consent decree, a Wall Street analyst says.